<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="6" ids="22652,29073">Ascorbic acid</z:chebi> has been shown to kill various <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines at pharmacologic concentrations </plain></SENT>
<SENT sid="1" pm="."><plain>We found that Epstein-Barr virus (EBV)-positive Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cells were more susceptible to <z:chebi fb="6" ids="22652,29073">ascorbic acid</z:chebi>-induced cell killing than EBV-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells or EBV-transformed lymphoblastoid cells (LCLs) </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="6" ids="22652,29073">Ascorbic acid</z:chebi> did not induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in any of the tested cells but did induce the production of reactive oxygen species and cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Previously, we showed that <z:chebi fb="0" ids="52717">bortezomib</z:chebi>, a <z:chebi fb="0" ids="52726">proteasome inhibitor</z:chebi>, induces cell <z:hpo ids='HP_0011420'>death</z:hpo> in LCLs and EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>We found that <z:chebi fb="6" ids="22652,29073">ascorbic acid</z:chebi> is strongly antagonistic for <z:chebi fb="0" ids="52717">bortezomib</z:chebi>-induced cell <z:hpo ids='HP_0011420'>death</z:hpo> in LCLs and EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells </plain></SENT>
<SENT sid="5" pm="."><plain>Finally, <z:chebi fb="6" ids="22652,29073">ascorbic acid</z:chebi> did not prolong survival of severe combined immunodefiency mice inoculated with LCLs either intraperitoneally or subcutaneously </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, while <z:chebi fb="6" ids="22652,29073">ascorbic acid</z:chebi> was highly effective at killing EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells and LCLs in vitro, it antagonized cell killing by <z:chebi fb="0" ids="52717">bortezomib</z:chebi> and was ineffective in an animal model </plain></SENT>
</text></document>